Eli Lilly

Rogers

Amgen

Merck

Pfizer

Thermo Fisher Scientific

West Pharmaceutical Services

Zealand Pharma

Viking Therapeutics

Amplify Weight Loss Drug & Treatment ETF

THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.

Tema Oncology ETF

Loncar Cancer Immunotherapy ETF

Tema Obesity & Cardiometabolic ETF

iShares Genomics Immunology and Healthcare ETF

Roundhill GLP-1 & Weight Loss ETF

ALPS Medical Breakthroughs ETF

Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.

Disruptive Theme of the Week – Breakthroughs in Medicine

Defiance Hotel Airline and Cruise ETF

Global X Funds - Global X E-commerce ETF

VanEck Video Gaming and eSports ETF

Harbor ETF Trust - Harbor Corporate Culture ETF

Harbor Corporate Culture Small Cap ETF

Harbor Corporate Culture Leaders ETF

Global X Video Games & Esports ETF 

Amplify Online Retail ETF

First Trust S-Network E-Commerce ETF

US Global Jets ETF

MUSQ Global Music Industry ETF

Roundhill Esports & Digital Entertainment ETF

Proshares Online Retail ETF

Proshares Pet Care ETF

Simplify Health Care ETF

SPDR S&P Retail ETF

With the completion of a close presidential election, roughly half of us are likely disappointed regardless of the winner. To counter the post-election blues, I identified some “happy” ETF themes to consider for investment.

Disruptive Theme of the Week: Happy Post-Election Themes

Amplify CWP Dividend & Option Income ETF

Amplify Cybersecurity ETF

As the ETF landscape continues to expand, more and more firms are crossing over significant AUM thresholds. That includes some now-veteran shops with strong, growing rosters, like Amplify ETFs.

Amplify ETFs Hits $10 Billion in Assets Amid New ETF Launches

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

Tap the Weight-Loss Drug Market With These ETFs

Fidelity MSCI Consumer Staples ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Aerospace & Defense ETF

iShares U.S. Healthcare ETF

iShares U.S. Consumer Goods ETF

Invesco Dynamic Pharmaceuticals ETF

Invesco Aerospace & Defense ETF

VanEck Vectors Pharmaceutical ETF

Global X Defense Tech ETF

Vanguard Consumer Staples ETF

Vanguard Utilities ETF

SPDR S&P Aerospace & Defense ETF

Consumer Staples Select Sector SPDR Fund

Utilities Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

ProShares Ultra Silver

Amplify Transformational Data Sharing ETF

Sonicshares Global Shipping ETF

First Trust SkyBridge Crypto Industry and Digital Economy ETF

GraniteShares 2x Long NVDA Daily ETF

Direxion Daily Nvda Bull 2X Shares

US Global Sea to Sky Cargo ETF

Strive US Semiconductor ETF

Global X Silver Miners ETF

Amplify Junior Silver Miners ETF

Aberdeen Standard Physical Silver Shares ETF

iShares Silver Trust

iShares MSCI Global Silver Miners ETF

VanEck Vectors Semiconductor ETF

Invesco PHLX Semiconductor ETF

iShares PHLX Semiconductor ETF

After a torrid risk-on run in the first quarter of 2024, markets cooled off a bit but ended the half still positive with mid-double-digit returns. Technology themes such as cryptocurrency and artificial intelligence helped propel markets higher.

Top Themes in the First Half of 2024: Crypto, Chips, Ships & Silver

Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

Principal Healthcare Innovators Index ETF

Fidelity MSCI Health Care ETF

First Trust Health Care AlphaDEX Fund

Amplify Treatments Testing & Advancements ETF

Global X Health Care Covered Call & Growth ETF

SPDR S&P Insurance ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Health Care ETF

SPDR Portfolio S&P 500 Growth ETF

SPDR Portfolio S&P 500 Value ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

SPDR S&P Pharmaceuticals ETF

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

Finding Opportunity in Unloved Healthcare ETFs

Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.

Play These New ETFs to Tap Lucrative Weight Loss Drug Market

On Tuesday, Amplify entered the weight loss ETF space with the launch of the Amplify Weight Loss Drug & Treatment ETF (THNR). THNR operates with a net expense ratio of 0.59%.

Amplify Debuts New Weight Loss Drug ETF

News for Amplify Weight Loss Drug & Treatment ETF ETF (THNR)